Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Extols NHS Asset In The ‘No Plan B’ Post-Brexit World

Executive Summary

The UK medtech industry is in a state of flux given the known unknowns of Brexit, perennial health-care funding pressures that will only exacerbate, and a menu of cost-saving initiatives that require medtech companies to adjust how they work with the National Health Service. Improving NHS and its role as a boon to smaller UK medtech companies is an important priority of industry.

You may also be interested in...

UK Viewpoint: AHSNs, AAR And Accelerators – Market Access & Innovation Update

Dr Charlie Davie, managing director of UCLPartners, a London-based Academic Health Science Partnership and one of the 15 UK Academic Health Science Networks, updates Medtech Insight on key changes in NHS market access policy this summer.

UK Medtechs Look Beyond Brexit To Long-Term Life-Science Strategy

The UK medtech industry is looking past Brexit to a time when the government's new Life Science Strategy has gone live. It also seeks better access to the NHS for medtech companies developing and launching innovations as the UK makes its own way in the world as a former EU member state.

UK Looks To Model New Medtech Strategy On US Successes

The UK medtech industry sees the US very much as both a vital market and learning ground for future business and health-care system successes. That was the tone at recent meetings involving the UK industry association, which is ramping up its US-facing activity.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts